Targeting CD20 in chronic lymphocytic leukemia
Myrna R Nahas, Jon E ArnasonBeth Israel Deaconess Medical Center, Boston, MA, USAAbstract: Chronic lymphocytic leukemia (CLL), the most common leukemia in adults, is standardly managed with chemotherapy in combination with the anti-CD20 antibody rituximab. In this review, we discuss the history, us...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2015-03-01
|
| Series: | Blood and Lymphatic Cancer : Targets and Therapy |
| Online Access: | http://www.dovepress.com/targeting-cd20-in-chronic-lymphocytic-leukemia-peer-reviewed-article-BLCTT |